Kartos Therapeutics, Inc.

Kartos Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company focused on the development of novel, targeted cancer therapies. According to its official website, the company is "Dedicated to the development of novel, targeted therapeutics that meaningfully improve the lives of patients with cancer." Its headquarters are in Redwood City, California, as recorded in public company data. The company's lead scientific focus is the MDM2-p53 interaction, which Kartos describes as "a compelling therapeutic target with potential to provide a new treatment option for patients across selected solid tumors and hematological malignancies." Its principal asset is navtemadlin, characterized by the company as "a novel, potent, and selective oral MDM2 inhibitor." Kartos is running active clinical studies of navtemadlin across selected solid tumor and hematological malignancy indications. Kartos operates as a clinical-stage developer rather than a commercial manufacturer; its activities center on drug discovery, clinical trials, and regulatory development of targeted oncology therapeutics. The company's website now identifies it as "Kartos Theraputics, an Ipsen company," indicating that it has been acquired by and operates within the Ipsen group. Ipsen is a global biopharmaceutical company listed on Euronext Paris under the ticker IPN, which makes Kartos a subsidiary within that corporate structure. Because Kartos is a privately held, clinical-stage subsidiary, detailed financial disclosures, product revenue figures, and commercial product lines are not publicly reported in the same way as for a commercial-stage pharmaceutical company. Its public profile rests on its pipeline, particularly navtemadlin, and on its integration into Ipsen's oncology portfolio. The company's stated mission and scientific rationale position it in the precision-oncology segment, targeting the MDM2-p53 pathway to restore tumor-suppressor function in cancers where that pathway is dysregulated.

Kartos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California, in the United States. Public company records identify it as a company in Redwood City, United States. The company was established to develop novel, targeted therapeutics for cancer, with a scientific focus on the MDM2-p53 protein-protein interaction. The MDM2-p53 axis is a well-known tumor-suppressor pathway: p53 is a key regulator of cell-cycle arrest and apoptosis, and MDM2 negatively regulates p53. Inhibiting MDM2 is intended to restore p53 activity in tumors that retain wild-type p53. Kartos has pursued this mechanism through its lead candidate, navtemadlin, which the company describes as a novel, potent, and selective oral MDM2 inhibitor. The company states that the MDM2-p53 interaction represents a compelling therapeutic target with potential to provide a new treatment option for patients across selected solid tumors and hematological malignancies, and it reports active clinical studies of navtemadlin in those areas. At some point in its corporate history, Kartos Therapeutics was acquired by Ipsen, a global biopharmaceutical company. The company's official website now presents the brand as "Kartos Theraputics, an Ipsen company," and the site's copyright notice reads "© 2026 Kartos Therapeutics, Inc. All rights reserved." This indicates that Kartos continues to operate as a named entity within the Ipsen group, with its oncology pipeline integrated into Ipsen's broader research and development organization. As a subsidiary, Kartos does not have its own public listing; Ipsen is listed on Euronext Paris under the ticker IPN. Because Kartos is a clinical-stage company and a subsidiary, its history is documented primarily through its pipeline progress and its acquisition by Ipsen rather than through commercial product launches or standalone financial reporting. The company's public identity rests on navtemadlin and on the MDM2-p53 scientific platform, which it continues to advance through active clinical studies.

• Kartos Therapeutics is identified in public company data as a company in Redwood City, United States.

• Kartos advances navtemadlin, described as a novel, potent, and selective oral MDM2 inhibitor, into active clinical studies.

• Kartos Therapeutics becomes part of Ipsen, presented on its website as 'Kartos Theraputics, an Ipsen company.'

Clinical-stage precision oncology company developing targeted therapies against the MDM2-p53 interaction; now an Ipsen company.

• Navtemadlin

  A novel, potent, and selective oral MDM2 inhibitor under active clinical study in selected solid tumors and hematological malignancies.

• 2026-08-21

  Ipsen completes acquisition of Kartos Therapeutics[3]益普生完成对Kartos Therapeutics的收购leaderpost.com

  Reported: 2026-08-21

  Ipsen announced on 21 August 2026 that it completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company, adding the late-stage MDM2 inhibitor navtemadlin, which is in Phase III clinical development for myelofibrosis.

1. 1Home | Kartos Theraputics, an Ipsen companykartosthera.com
2. 2Kartos Therapeutics, Inc. (United States) - Wikidatawikidata.org
3. 3益普生完成对Kartos Therapeutics的收购leaderpost.com
4. 4Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline | Company Announcement | Investegateinvestegate.co.uk
5. 5Ipsen Pharma: Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipelinefinanznachrichten.de